Global law firm Hogan Lovells Cadwalader has advised Neva SGR S.p.A., the venture capital company of the Intesa Sanpaolo Group, on its investment, through the Neva II Fund, in Nouscom AG, a Swiss biotech company developing next-generation immunotherapies.
The investment forms part of a €120 million Series D financing round, in which Neva SGR co-invested alongside leading international funds, including Angelini Industries (through Angelini Investments) and the European Investment Bank (through Aurea, its co-investment fund with Angelini Ventures).
The proceeds will support the advancement of NOUS-209, an investigational neoantigen-based cancer immunotherapy, through a global clinical trial aimed at cancer interception in individuals with Lynch syndrome.
The Hogan Lovells Cadwalader team advising on the transaction was led by partner Paola Barometro and included associate Edoardo Pea.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
